scholarly journals Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis

2019 ◽  
Vol 39 (3) ◽  
pp. 493-499 ◽  
Author(s):  
Yan-yan Zhong ◽  
Jin-chun Li ◽  
Ya-ling Liu ◽  
Xiao-bo Zhao ◽  
Musa Male ◽  
...  
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Preterm Infants ◽  
Bronchopulmonary Dysplasia ◽  
Pulmonary Surfactant ◽  
Distress Syndrome ◽  
Meta Analysis ◽  
Neonatal Respiratory Distress Syndrome ◽  
Intratracheal Administration ◽  
Neonatal Respiratory Distress

scholarly journals Lung ultrasound in diagnosing neonatal respiratory distress syndrome: a meta-analysis

2019 ◽  
Vol 59 (6) ◽  
pp. 340-8
Author(s):  
Hanum Ferdian ◽  
Dian Ibnu Wahid ◽  
Samad Samad ◽  
Anggun Esti Wardani ◽  
Guntur Surya Alam ◽  
...  
Keyword(s):  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Sensitivity And Specificity ◽  
Diagnostic Tool ◽  
Distress Syndrome ◽  
Lung Ultrasound ◽  
Meta Analysis ◽  
Neonatal Respiratory Distress Syndrome ◽  
Inclusion Criteria ◽  
Neonatal Respiratory Distress

Background Neonatal respiratory distress syndrome (NRDS) is commonly diagnosed by clinical sign and symptoms, blood gas analysis, and chest x-ray. In the past, lung ultrasound (LUS) was not standard for NRDS examination. Many studies show that ultrasound diagnostic tool for NRDS is accurate, reliable, low cost, easy to use, and safe because due to no ionizing radiation. Objective To determine the sensitivity and specificity of LUS in diagnosing NRDS. Methods This meta-analysis study was conducted LUS as a diagnostic tool for NRDS. Inclusion criteria were all studies from PubMed, Embase, and The Cochrane Library, without any limitation on published journals, as well as using keywords or search terms of ultrasound, neonatal, and respiratory distress syndrome. Statistical analysis was undertaken using MedCalc® version 18.2 software. Results Seven studies with a total of 580 patients met the inclusion criteria. Proportional meta-analysis obtained random effects models, with total sensitivity of LUS was 97.2% (95% CI for I2 74.24 to 92.88; P<0.0001) and specificity of LUS was 94.8% (95% CI for I2 88.60 to 98.03; P<0.00001). Conclusion Lung ultrasound should be considered as a diagnostic tool for NRDS because it is high in sensitivity and specificity, inexpensive, safe, as well as limited radiation exposure.

scholarly journals Expression of Pulmonary Surfactant-Associated Protein B in Neonatal Respiratory Distress Syndrome

2013 ◽  
Vol 32 (2) ◽  
pp. 146-151
Author(s):  
Xiaojuan Yin ◽  
Yan Wang ◽  
Lu Xie ◽  
Xiangyong Kong ◽  
Chunzhi Wang ◽  
...  
Keyword(s):  
Protein Expression ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Mrna Expression ◽  
Pulmonary Surfactant ◽  
Distress Syndrome ◽  
Neonatal Respiratory Distress Syndrome ◽  
Control Group ◽  
Neonatal Respiratory Distress ◽  
Protein B

Summary Background: The aim of this study was to investigate the role of pulmonary surfactant-associated protein B (SP-B) expression in the pathogenesis of neonatal respiratory distress syndrome (RDS) via detecting the protein and mRNA expression of SP-B. Methods: A total of 60 unrelated neonates who died of RDS were chosen as the RDS group and then subgrouped into ≤32 weeks group, 32∼37 weeks group and ≥37 weeks group (n=20). Sixty neonates who died of other diseases were enrolled as controls and subdivided into 3 matched groups based on the gestational age. Western blot assay and RT-PCR were employed. Results: In the RDS group, SP-B protein expression was reduced or deficient in 8 neonates of which 6 had no SP-B protein expression. In the control group, only 1 had reduced SP-B protein expression. The reduced or deficient SP-B protein expression in 9 neonates of both groups was noted in the ≥37 weeks group. In the RDS group, the SP-B mRNA expression was significantly lower than that in the control group. In the ≤37 weeks group, SP-B mRNA expression was comparable between the RDS group and control group. In the 32∼37 weeks group, the SP-B mRNA expression in the RDS group was significantly reduced when compared with the control group. In the ≥37 weeks group, the SP-B mRNA expression in the RDS group was dramatically lower than that in the control group. Conclusions: Alteration of SP-B expression is present at transcriptional and translational levels. Reduction of SP-B mRNA and protein expression is involved in the pathogenesis of RDS.

scholarly journals Practical Considerations in the Selection and Use of Pulmonary Surfactant Therapy for Neonatal Respiratory Distress Syndrome in the Intensive Care Setting

2006 ◽  
Vol 11 (3) ◽  
pp. 161-168
Author(s):  
Karen E. Corff ◽  
Steve Greubel ◽  
Debra L. McCann ◽  
Richard Williams ◽  
Dwight L. Varner
Keyword(s):  
Adverse Effects ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Nurse Practitioners ◽  
Pulmonary Surfactant ◽  
Distress Syndrome ◽  
Response To Therapy ◽  
Lung Damage ◽  
Neonatal Respiratory Distress Syndrome ◽  
Neonatal Respiratory Distress

Pulmonary surfactant is the treatment of choice for neonatal respiratory distress syndrome, as it significantly reduces infant morbidity and mortality. Extensive clinical trials compare the surfactant products and their optimal usage, but often the practical administration issues are less frequently discussed. Herein, a panel of respiratory therapists and neonatal nurse practitioners share their experience regarding surfactant usage. According to the panelists, the primary criteria for surfactant selection are the ability to rapidly decrease ventilatory requirements toward extubation, a low incidence of adverse effects, cost-effectiveness, and ease of use. In most cases, surfactant is most efficacious when given as early as possible where indicated. The surfactant products differ in their storage, handling, preparation, and administration traits, and this may affect rapid dosing of the surfactant during acute treatment. During and after administration, optimal response to therapy depends on efficient management of ventilator settings, which requires vigilant monitoring of the infant. Common adverse effects include endotracheal tube reflux, bradycardia, and desaturation. Using a surfactant which requires a small dosing volume may decrease the incidence of these adverse effects. An emerging trend in clinical practice is the quick extubation of the infant to nasal continuous positive airway pressure after surfactant administration. This practice can reduce the need for ventilation and reduce the risk of ventilator-related lung damage. Nebulization of surfactant may be a future avenue of delivery, but further research is required to determine its precise role. The practical considerations summarized in this discussion may be useful for other clinicians in their own practice.

scholarly journals Application Value of a New Lung Ultrasound Scoring Method in Neonatal Respiratory Distress Syndrome Treatment 

2020 ◽  
Author(s):  
Qiu-xia Jiang ◽  
Li-jing Shi ◽  
Long-yuan Shen ◽  
Xiao-qing Li ◽  
Rong-sen Hung ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Pulmonary Surfactant ◽  
Distress Syndrome ◽  
Lung Ultrasound ◽  
Neonatal Respiratory Distress Syndrome ◽  
Scoring Method ◽  
Neonatal Respiratory Distress ◽  
Pre Treatment

Abstract We studied a 14-zone lung ultrasound scoring method to quantify the efficiency of pulmonary surfactant treatment and to determine the timing of mechanical ventilation in neonates with neonatal respiratory distress syndrome. In this prospective study, we identified 88 neonates who received pulmonary surfactant replacement therapy. We measured surfactant efficiency using the 14-zone scoring method pre-treatment and at 12 h, 24 h, 48 h, and 72 h post-treatment. The ultrasound score was inversely associated with pulmonary surfactant treatment. We also identified 67 neonates on mechanical ventilation. We applied the scoring method when the infants met criteria for ventilator withdrawal. A comparison of pre-treatment to 12 h post-treatment showed that scoring method was significantly different (t = 4.08, P < 0.05); other scoring methods did not differ (P > 0.05). Thus, the scoring method performed better on withdrawal time. A score of 41.0 was defined as the threshold for risk of withdrawal failure with 92.36% sensitivity and 93.80% specificity, with an area under the curve of 0.955. Conclusion: The new 14-zone lung ultrasound scoring method improved scoring on the efficacy of pulmonary surfactant and had good diagnostic efficiency for timing the removal of mechanical ventilation in neonatal respiratory distress syndrome.

Sign in / Sign up

Export Citation Format

Share Document